Understanding how Shoc2 affects cell signaling and movement
Mechanisms and functions of Shoc2-transduced cellular signals
['FUNDING_OTHER'] · UNIVERSITY OF KENTUCKY · NIH-10832063
This study is looking at how a protein called Shoc2 helps control signals in our cells that can affect conditions like cancer and birth defects, so we can better understand how problems with this protein might lead to these diseases.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-10832063 on ClinicalTrials.gov |
What this research studies
This research investigates the role of the Shoc2 protein in regulating important cellular signals that affect cell behavior, particularly in relation to conditions like cancer and congenital defects. By studying how Shoc2 interacts with other proteins to transmit signals, researchers aim to uncover new insights into the mechanisms that lead to diseases. The approach involves detailed molecular analysis and experimentation to identify how disruptions in Shoc2 function can impact cell adhesion and movement, which are critical for normal development and disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with congenital defects or cancers related to dysregulated cell signaling.
Not a fit: Patients with conditions unrelated to cell signaling or those who do not have congenital defects or cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic targets for treating cancers and congenital abnormalities.
How similar studies have performed: Previous research has shown promising results in understanding similar cellular signaling mechanisms, indicating that this approach has the potential for significant breakthroughs.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GALPERIN, EMILIA — UNIVERSITY OF KENTUCKY
- Study coordinator: GALPERIN, EMILIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer